RSS | ATOM

PENNY STOCK PROFESSOR

 

pennystock...'s Profile

PennyStockProfessor.com is brilliant at finding companies that are over-looked by the market. This means that there is no surge of profits and the stock is typically sold very low. This is great for our investors who get in early before the stock has a chance to make major explosions of growth!

I Recommend...

  • Fri
  • 11/6/2009
  • 7:02 PM
  • Woos
    & Boos
  • 0
    WOOS
  • 0
    BOOS
  • PharmAthene Inc (NYSE AMEX:PIP) to Release Q3 2009 Earnings November 12

     

    PharmAthene, Inc. (NYSE AMEX:PIP) will release the third quarter earnings for 2009 on Thursday, November 12.  The company’s management will be conducting a conference call at 11:00 am ET that morning to discuss the financial results.  Interested parties may hear the call by dialing 866.700.7173 or 617.213.8838 for international callers.  The pass code for the call will be 45158592.  To hear a replay of the call, dial 888.286.8010 or 617.801.6888 for international callers and enter the pass code 97434742.  The replay will be available from 2:00 pm ET November 12 to 11:59 pm ET December 12, 2009.  A webcast will also be available on the company’s website,www.PharmAthene.com, on the Investor Relations portion of the site for thirty days following the conference.

     

    Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.

     

    PharmAthene, Inc. (PharmAthene), formerly Healthcare Acquisition Corp., is a biodefense company engaged in the development and commercialization of medical countermeasures against biological and chemical weapons. The Company has five product candidates in various stages of development, which include SparVax, Valortim, Protexia, RypVax and a third generation recombinant protective antigen (rPA) anthrax vaccine. SparVax is a second generation rPA anthrax vaccine. Valortim is a fully human monoclonal antibody for the prevention and treatment of anthrax infection. Protexia mimics a natural bioscavenger for the treatment or prevention of nerve agent poisoning by organophosphate compounds, including nerve gases and pesticides. RypVax is a recombinant dual antigen vaccine for pneumonic and bubonic plague. On April 2, 2008, the Company acquired Avecia’s biodefense vaccines business from Avecia Biologics Limited and certain of its affiliates.

     

    Follow us on Twitter: http://www.twitter.com/pennystockspro

     

    Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.

     

    About Us

     

    Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.

     

    Please click here to read the full disclaimer.

     

     

    staff@pennystockprofessor.com
    www.pennystockprofessor.com 

    Empty Image



    • Print
    • Bookmark and Share

    Comments

     



     

     

    Recent Stocks Posts